Evoltra licensed to treat ALL

Evoltra (clofarabine) is an antineoplastic deoxyadenosine analogue that has been approved for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where no other treatment option is expected to produce a durable response.

In a phase II clinical study involving 61 patients with refractory or relapsed ALL, clofarabine 52mg/m2 given intravenously over two hours daily for five consecutive days and repeated every two to six weeks produced a response rate of 30%. Among these, there were seven complete remissions, five complete remissions without platelet recovery and six partial remissions.

Evoltra 1mg/ml concentrate for solution for infusion is presented in 20ml vials, in packs of four at a cost of £4800.00.

Further information: Bioenvision Ltd, 10 Lochside Place, Edinburgh Park, Edinburgh EH12 9RG. Tel: (0131) 248 3667.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...